Reviva Pharmaceuticals Holdings, Inc. (RVPH)

OTCMKTS · Delayed Price · Currency is USD

0.5000

+0.00503 (1.02%)

At close: Oct 9, 2026

RVPH Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	6.78	8.49	7.89	8.08	5.36	5.25
Research & Development	6.7	11.71	22.91	31.42	22.87	4.85
Operating Expenses	13.48	20.2	30.8	39.5	28.23	10.1
Operating Income	-13.48	-20.2	-30.8	-39.5	-28.23	-10.1
Interest Expense	-0.01	-0.01	-0.02	-0.03	-	-0
Interest & Investment Income	0.47	0.31	0.36	0.4	0.18	-
Other Non Operating Income (Expenses)	0.01	0.06	0.56	-0.1	-0.19	1.59
Pretax Income	-13.01	-19.85	-29.9	-39.24	-28.24	-8.52
Income Tax Expense	0.01	0.02	0.02	0.02	0.02	0.01
Net Income	-13.02	-19.86	-29.92	-39.26	-28.26	-8.52
Net Income to Common	-13.02	-19.86	-29.92	-39.26	-28.26	-8.52
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	7	4	2	1	1	1
Shares Outstanding (Diluted)	7	4	2	1	1	1
Shares Change	241.87%	114.96%	41.84%	21.94%	31.95%	383.10%
EPS (Basic)	-1.75	-5.48	-17.73	-32.99	-28.96	-11.52
EPS (Diluted)	-1.75	-5.48	-17.73	-32.99	-28.96	-11.52
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EBITDA	-	-	-	-	-	-10.1
D&A For EBITDA	-	-	-	-	-	0
EBIT	-13.48	-20.2	-30.8	-39.5	-28.23	-10.1